Promoting research partnerships 

to improve veterans’ health

DoD Gulf War Illness Research Program New Investigator Award

3 Aug 2018 11:34 AM | Hawk Tran (Administrator)

The FY18 Defense Appropriation provides $21 million (M) to the Department of Defense Gulf War Illness Research Program (GWIRP) to support high-impact research that will identify effective treatments and accelerate their clinical application, identify objective markers for improved definition and diagnosis, and/or provide a better understanding of the pathobiology underlying the complex of Gulf War Illness symptoms. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY18 GWIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the website.

New Investigator Award – Letter of Intent due October 18, 2018

  • PIs may apply under one of the following three eligibility categories:
  • Transitioning Postdoctoral Fellow: Senior postdoctoral fellows who have completed at least 3 years of postdoctoral training.
  • Early-Career Investigator: Independent investigators within 5 years since their last training position.
  • New GWI Researcher: Established independent investigators who have received less than $300,000 in federally funded, non-mentored GWI research
  • Submission of a Letter of Intent is required.
  • Encourages applications from early stage and established investigators new to the field of GWI research.
  • Previous experience in GWI research is not required; however, collaborations with experienced GWI researchers are encouraged.
  • Preliminary data are not required, and if provided, do not necessarily have to come from the GWI research field.
  • Studies that provide outcomes clearly translatable to clinical use are encouraged.
  • Clinical trials are not allowed.
  • The maximum allowable funding for the entire period of performance is $500,000 for direct costs.
  • The maximum period of performance is 3 years.
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the website.  The application package containing the required forms for each award mechanism will also be found on  A listing of all CDMRP funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420. 

Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at  For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (

Point of Contact:

CDMRP Help Desk

1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |

Powered by Wild Apricot Membership Software